Frankfurt | Reuters—Bayer confirmed its full-year forecast for earnings and cash flow on Monday despite slow business at its crop science and consumer health divisions.
“Our Crop Science and Consumer Health divisions expect a slow start to the year due to market dynamics, but we feel confident in our full-year targets and the direction of our businesses,” CEO Bill Anderson said in his speech for the April 26 annual general meeting, which was posted on the company’s website on Monday.
The CEO reiterated that 2024 earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off items and currency swings, would decline between three and nine per cent and that free cash flow would reach 2-3 billion euros (C$2.9 billion to $4.7 billion) up from 1.3 billion (C$1.9 billion) last year.
Read Also
Carney visits Asia to forge new alliances and reduce U.S. dependence
Canada’s Prime Minister Mark Carney embarks on his first official visit to Asia on Friday in an attempt to deepen trade and security ties at a time when the North American country is struggling to lessen its overwhelming dependence on the U.S. and redefine its foreign policy in pursuit of new markets.
Anderson will face investor question at the AGM over his decision in March to pause plans to break apart the German diversified group, which includes a large pharmaceuticals business, for up to three years. He has said he would instead focus on a management overhaul, debt reduction and fending off litigation.
Major Bayer shareholder Harris Associates has told Reuters it strongly supports the decision to suspend work on breaking up the group.
